Orthofix Medical (OFIX) investor relations material

Strategic vision and growth priorities

• Focused on disciplined, profitable growth through innovation, operational excellence, and capital deployment in high-return areas.

• Building on a comprehensive med tech portfolio spanning spinal solutions, biologics, limb reconstruction, and advanced surgical navigation.

• Emphasis on sustainable, above-market growth with differentiated technologies and broad commercial reach.

• Clear strategy led by an experienced management team, prioritizing investment in areas with strong competitive advantages.

• Vision to be the unrivaled partner in med tech, delivering life-changing solutions and exceptional experiences.

Financial performance and guidance

• Q1 2026 pro forma net sales reached $196.4M, up 2.7% YoY on a constant currency basis; adjusted EBITDA was $9.7M.

• Non-GAAP pro forma adjusted gross margin improved to 70.7%, a 40 basis point increase over the prior year.

• Full-year 2026 guidance projects net sales of $838M–$848M and adjusted EBITDA of $90M–$93M.

• Free cash flow for Q1 2026 was negative at $(28.3)M, with ongoing efforts to drive toward positive free cash flow.

• Continued improvement in working capital management and reduction in inventory days on hand.

Business segment highlights

• Therapeutic Solutions net sales grew 5% YoY, driven by cross-selling and new surgeon conversions.

• Global Spine Fixation net sales increased 6% YoY, with strong distributor performance and ongoing product launches.

• Limb Reconstruction net sales rose 3% YoY, supported by new product releases and expanded distribution.

• Enabling Technologies, including 7D FLASH Navigation, positioned for significant share capture in a fast-growing market.